Strategic ambiguities with "stem cells"

July 2009. While many ethical questions surrounding the use of stem cells have been satisfactorily answered, a number of unresolved methodological and technical issues hamper applications in the pharmacceutical industry. Where are the stumbling blocks of today? What is Merck’s and Merck Serono’s approach, and with what prospects? Bernd Kirschbaum, Head of Global Discovery and Early Development for Merck Serono and points to strategic ambiguities in technology development.Reading time: 4 min

Read Now:
1,00 EUR (incl. 7% VAT)

Back to section